

Supplementary material has been published as submitted. It has not been copyedited, or typeset by Acta Oncologica

Supplementary Table 1. Patient demographics and outcomes

Variable	Pandemic group (n=82)	Non-pandemic group (n=218)	p-value
Age	69.2± 9.1	68.2±9.9	0.385
BMI	26.2±4.4	26.7±4.8	0.414
Gender			0.503
Female	32 (39.0%)	76 (34.9%)	
Male	50 (61.0%)	142 (65.1%)	
CCI			0.791
0	25 (30.5%)	56 (25.7%)	
1	26 (31.7%)	78 (35.8%)	
2	18 (30.0%)	53 (24.3%)	
≥3	13 (15.9%)	31 (14.2%)	
DLCO (SD)	79.8±19.3	79.6±18.8	0.92
Waiting time (IQR)	21 (14-33)	22 (14-29)	0.947
Surgical technique			0.579
RATS	10 (12.2%)	26 (11.9%)	
VATS	34 (41.5%)	77 (35.3%)	
Thoracotomy	38 (46.3%)	115 (52.8%)	
Resection			0.003
Pneumonectomy	1 (1.2%)	2 (0,9%)	
Sublobar	14 (17.1%)	11 (5.0%)	
Lobar	67 (81.7%)	205 (94.0%)	
Stage			0.439
I	51 (62.2%)	122 (56.0%)	
II	15 (18.3%)	56 (25.7%)	
III	15 (18.3%)	35 (16.1%)	
IV	0 (0.0%)	2 (0.9%)	
Undefined	1 (1.2%)	3 (1.4%)	
Histology			0.288

SCC	21 (25.6%)	53 (56.0%)	
Adenocarcinoma	53 (64.6%)	127 (58.3%)	
Carcinoid	4 (4.9%)	14 (6.4%)	
Other	4 (4.9%)	24 (11.0%)	
Length of stay (IQR)	5 (3-7)	5 (4-7)	0.162
30-d mortality	0 (0%)	0 (0%)	N/A
90-d mortality	1 (1.2%)	1 (0.5%)	0.490

CCI: Modified Charlson comorbidity index, FEV1: first second forced expiratory volume, DLCO: diffusing capacity, Waiting time: days from referral to surgery, RATS: robotic assisted thoracoscopy, VATS: video assisted thoracoscopy, SCC: Squamous cell carcinoma, Stage: pathological stage by TNM8 classification[17]